Leucine-rich repeat kinase 2 biomarkers for Parkinson's disease

被引：0

作者：

Dzamko, Nicolas ^{[1
]}

机构：

[1] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Camperdown, NSW, Australia

来源：

BIOCHEMICAL JOURNAL | 2025年 / 482卷 / 11期

关键词：

MITOCHONDRIAL-DNA DAMAGE; RAB10; PHOSPHORYLATION; ALPHA-SYNUCLEIN; LRRK2; MUTATIONS; BIS(MONOACYLGLYCEROL)PHOSPHATE; EXOSOMES; MONITOR; CELLS; GENE;

D O I：

10.1042/bcj20253099

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has emerged as a promising therapeutic target for the treatment of neurodegenerative Parkinson's disease (PD). Data from a multitude of pre-clinical models are supportive of a potential role for LRRK2 therapies to ameliorate cellular dysfunctions found in PD, and small molecules to inhibit LRRK2 kinase activity, as well as antisense oligonucleotides to target the protein itself, are in clinical trials. Despite this, exactly how LRRK2 contributes to PD pathogenesis remains to be determined, and definitive biomarkers to track LRRK2 function are still required. Such biomarkers can be useful for monitoring the pharmacodynamic response of LRRK2 therapeutics and/or understanding the relationship between LRRK2 and the clinical progression of PD. Moreover, biomarkers that can identify increased LRRK2 levels or activity beyond just carriers of pathogenic LRRK2 mutations will be important for expanding LRRK2 therapeutics to other PD populations. This review summarizes recent findings regarding biomarkers of LRRK2.

引用

页码：711 / 722

页数：12

共 98 条

[21] Effect of selective LRRK2 kinase inhibition on nonhuman primate lung [J].

Fuji, Reina N. ;

Flagella, Michael ;

Baca, Miriam ;

Baptista, Marco A. S. ;

Brodbeck, Jens ;

Chan, Bryan K. ;

Fiske, Brian K. ;

Honigberg, Lee ;

Jubb, Adrian M. ;

Katavolos, Paula ;

Lee, Donna W. ;

Lewin-Koh, Sock-Cheng ;

Lin, Tori ;

Liu, Xingrong ;

Liu, Shannon ;

Lyssikatos, Joseph P. ;

O'Mahony, Jennifer ;

Reichelt, Mike ;

Roose-Girma, Merone ;

Sheng, Zejuan ;

Sherer, Todd ;

Smith, Ashley ;

Solon, Margaret ;

Sweeney, Zachary K. ;

Tarrant, Jacqueline ;

Urkowitz, Alison ;

Warming, Soren ;

Yaylaoglu, Murat ;

Zhang, Shuo ;

Zhu, Haitao ;

Estrada, Anthony A. ;

Watts, Ryan J. .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (273) :273ra15

[22] Selective Inhibitors of G2019S-LRRK2 Kinase Activity [J].

Garofalo, Albert W. ;

Bright, Jessica ;

De Lombaert, Stephane ;

Toda, Alyssa M. A. ;

Zobel, Kerry ;

Andreotti, Daniele ;

Beato, Claudia ;

Bernardi, Silvia ;

Budassi, Federica ;

Caberlotto, Laura ;

Gao, Peng ;

Griffante, Cristiana ;

Liu, Xinying ;

Mengatto, Luisa ;

Migliore, Marco ;

Sabbatini, Fabio Maria ;

Sava, Anna ;

Serra, Elena ;

Vincetti, Paolo ;

Zhang, Mingliang ;

Carlisle, Holly J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (23) :14821-14839

[23] Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson's disease [J].

Gomes, Sara ;

Garrido, Alicia ;

Tonelli, Francesca ;

Obiang, Donina ;

Tolosa, Eduardo ;

Marti, Maria Jose ;

Ruiz-Martinez, Javier ;

Vinagre-Aragon, Ana ;

Hernandez-Eguiazu, Haizea ;

Croitoru, Ioana ;

Marshall, Vicky L. ;

Koenig, Theresa ;

Hotzy, Christoph ;

Hsieh, Frank ;

Sakalosh, Marianna ;

Tengstrand, Elizabeth ;

Padmanabhan, Shalini ;

Merchant, Kalpana ;

Bruecke, Christof ;

Pirker, Walter ;

Zimprich, Alexander ;

Sammler, Esther .

NPJ PARKINSONS DISEASE, 2023, 9 (01)

[24] Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease [J].

Gonzalez-Hunt, C. P. ;

Thacker, E. A. ;

Toste, C. M. ;

Boularand, S. ;

Deprets, S. ;

Dubois, L. ;

Sanders, L. H. .

SCIENTIFIC REPORTS, 2020, 10 (01)

[25] Human Mitochondrial DNA: Particularities and Diseases [J].

Habbane, Mouna ;

Montoya, Julio ;

Rhouda, Taha ;

Sbaoui, Yousra ;

Radallah, Driss ;

Emperador, Sonia .

BIOMEDICINES, 2021, 9 (10)

[26] Neuropathology underlying clinical variability in patients with synucleinopathies [J].

Halliday, Glenda M. ;

Holton, Janice L. ;

Revesz, Tamas ;

Dickson, Dennis W. .

ACTA NEUROPATHOLOGICA, 2011, 122 (02) :187-204

[27] Development of a highly potent and selective degrader of LRRK2 [J].

Hatcher, John M. ;

Zwirek, Monika ;

Sarhan, Adil R. ;

Vatsan, Prasanna S. ;

Tonelli, Francesca ;

Alessi, Dario R. ;

Davies, Paul ;

Gray, Nathanael S. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 94

[28] Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study [J].

Healy, Daniel G. ;

Falchi, Mario ;

O'Sullivan, Sean S. ;

Bonifati, Vincenzo ;

Durr, Alexandra ;

Bressman, Susan ;

Brice, Alexis ;

Aasly, Jan ;

Zabetian, Cyrus P. ;

Goldwurm, Stefano ;

Ferreira, Joaquim J. ;

Tolosa, Eduardo ;

Kay, Denise M. ;

Klein, Christine ;

Williams, David R. ;

Marras, Connie ;

Lang, Anthony E. ;

KWszolek, Zbigniew ;

Berciano, Jose ;

Schapira, Anthony H. V. ;

Lynch, Timothy ;

Bhatia, Kailash P. ;

Gasser, Thomas ;

Lees, Andrew J. ;

Wood, Nicholas W. .

LANCET NEUROLOGY, 2008, 7 (07) :583-590

[29] Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease [J].

Henderson, Michael X. ;

Sengupta, Medha ;

Trojanowski, John Q. ;

Lee, Virginia M. Y. .

ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2019, 7 (01)

[30] LRRK2 activation controls the repair of damaged endomembranes in macrophages [J].

Herbst, Susanne ;

Campbell, Philip ;

Harvey, John ;

Bernard, Elliott M. ;

Papayannopoulos, Venizelos ;

Wood, Nicholas W. ;

Morris, Huw R. ;

Gutierrez, Maximiliano G. .

EMBO JOURNAL, 2020, 39 (18)

← 1 2 3 4 5 6 7 8 9 10 →